Health Catalyst, Inc. (HCAT)

Health Catalyst's stock price has declined significantly over the past six months. Key events impacting the stock include strong financial performance reported in Q3 2024, exceeding guidance for revenue and adjusted EBITDA, and a strategic focus on the Ignite platform and a cybersecurity acquisition. The company reported a solid first quarter in 2025, exceeding guidance for both revenue and adjusted EBITDA, with the Ignite platform fueling growth. Revenue was up 6% year-on-year in Q4 2024, and full-year EBITDA guidance exceeded expectations. Revenue was above Wall Street expectations in Q3 CY2025, though flat year-over-year. In Q4 2023, the company announced a 10% headcount reduction due to macroeconomic headwinds and worsening operating losses.

Seasonal chart analysis for Health Catalyst, Inc. suggests a period of seasonal strength, with a "Buy Date of May 10 and a Sell Date of July 29" resulting in positive returns above the S&P 500 Total Return Index over the past five years. This timeframe aligns with the broader Healthcare sector's seasonal strength, which typically runs from April 25 to December 4. However, this analysis is based on only five years of data.

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. It offers a suite of solutions, including the Ignite platform, for data integration, advanced analytics, and data-driven decision-making. Its applications support various functions, and the company provides professional services. Health Catalyst's clients include academic medical centers, integrated delivery networks, community hospitals, large physician practices, health insurers, and other risk-bearing entities.

Health Catalyst, Inc. is headquartered in South Jordan, Utah, with additional offices in Los Angeles and San Francisco. The company primarily serves healthcare organizations in the United States, but its offerings are used by over 1,000 organizations worldwide.

Health Catalyst maintains a positive brand reputation, evidenced by recognitions such as Inc. Best Workplaces, Deloitte Best Managed Companies, and a Best in KLAS award for analytics solutions. KLAS Research reviews indicate high ratings for Health Catalyst's software products and services. The company hosts the annual Catalyst Awards and the Health Catalyst Analytics Summit (HAS). No specific negative events significantly impacting Health Catalyst's brand reputation were identified in the past year.

Health Catalyst, Inc. has a high level of institutional ownership, with 310 institutional owners holding over 91% of the company. Major institutional shareholders include First Light Asset Management, LLC, BlackRock, Inc., Vanguard Group Inc, Whetstone Capital Advisors, LLC, Impax Asset Management Group plc, Dimensional Fund Advisors Lp, Geode Capital Management, Llc, and PRIMECAP Odyssey Aggressive Growth Fund. Individual insiders have shown more buying than selling activity in the past three months.